The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990.

Through integrated and comprehensive programs, MD Anderson advances transformative discovery, prevention, translational and clinical research. We aim to provide a deeper understanding of all cancer types, including rare cancers not often studied or treated elsewhere, to ultimately lead to meaningful benefits for patients and society. In fiscal year 2024, MD Anderson invested $1.3 billion in research efforts. MD Anderson also is home to world’s largest oncology clinical trials program, with more than 1,500 ongoing trials in FY24, and 27 drugs tested at MD Anderson received FDA approval in FY24.

Through partnership with our patients, our scientists and clinicians seamlessly collaborate to develop breakthroughs that transform the field. Discoveries from our labs are swiftly translated into new therapies in the clinic, and insights from the clinic inform our laboratory work in real time. At every step, a rapidly growing team of data scientists provide insights, processes and tools that better inform and accelerate studies. Our culture of collaboration provides early-career researchers accessible mentorship and hands-on training from some of the most brilliant minds in the world across the spectrum of cancer research and care.

Latest from The University of Texas MD Anderson Cancer Center


Dr Loghavi on the Expansion of Genetically-Defined Subtypes in AML

September 20, 2023

Sanam Loghavi, MD, discusses the expansion of genetically-defined categories of acute myeloid leukemia in the World Health Organization classification, and how this affects the diagnosis of patients in this space.

Ongoing Research Aims to Address Further Questions on Fixed-Duration Therapy in CLL

September 20, 2023

Alessandra Ferrajoli, MD, discusses the continued investigation of fixed-duration therapy as a frontline approach for patients with CLL, highlights both the pros and cons of this strategy, and touches on the unanswered questions regarding fixed-duration therapy that ongoing research aims to address.

Jones and Somaiah Review the Rationale and Design of the Peak Trial in GIST

September 18, 2023

Drs Jones and Somaiah discuss unmet needs in GIST that the Peak trial seeks to answer; the advantages of the methods and design of this trial; and how the tolerable safety profile of bezuclastinib plus sunitinib supports further research with this combination.

Dr. Strati on the Investigation of Immunotherapy Combinations in Lymphoma

September 15, 2023

Paolo Strati, MD, discusses several ongoing investigations aiming to improve upon current immunotherapy combinations, highlighting the introduction of novel regimens into the treatment landscape of follicular lymphoma.

Dr Westin on the Updated Treatment Paradigm in Second-Line LBCL

September 13, 2023

Jason R. Westin, MD, director, discusses how the approval of CAR T-cell therapies in the second-line setting has radically shifted preferred treatment approaches in relapsed/refractory large B-cell lymphoma.

Dr Garcia-Manero on the Efficacy of Luspatercept in Transfusion-Dependent MDS

September 09, 2023

Guillermo Garcia-Manero, MD, discusses the key efficacy findings from the phase 3 COMMANDS trial evaluating luspatercept-aamt in patients with myelodysplastic syndrome who were erythropoiesis-stimulating agent naïve and red blood cell transfusion dependent.

Ponatinib Increases MRD-Negative CR Rate in Ph+ ALL

September 06, 2023

The addition of the TKI ponatinib to reduced-intensity chemotherapy led to an increase in minimal residual disease-negative complete remission rate at the end of induction compared with imatinib among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

x